Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.58 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31137445 | 1.00 | PDPK1 (0.58) | PDPK1SRD5A1TRPV1ACHECA12 | |
| SCHEMBL1415389 | 1.00 | PDPK1 (0.58) | PDPK1SRD5A1TRPV1ACHECA12 | |
| SCHEMBL28460491 | 0.90 | PDPK1 (0.46) | PDPK1SRD5A1CAMK2A | |
| SCHEMBL6497708 | 0.86 | PDPK1 (0.58) | PDPK1SRD5A1ACHEKDM1A | |
| SCHEMBL30985322 | 0.86 | PDPK1 (0.58) | PDPK1SRD5A1ACHEKDM1A | |
| SCHEMBL15447552 | 0.86 | PDPK1 (0.58) | PDPK1SRD5A1ACHEKDM1A | |
| SCHEMBL24994971 | 0.82 | SRD5A1 (0.42) | PDPK1SRD5A1TRPV1CA12CA1 | |
| SCHEMBL8246017 | 0.82 | SRD5A1 (0.42) | PDPK1SRD5A1TRPV1CA12CA1 | |
| SCHEMBL22547419 | 0.80 | PDPK1 (0.59) | PDPK1SRD5A1TRPV1ACHECA12 | |
| SCHEMBL1530500 | 0.79 | GRIA2 (0.44) | SRD5A1TRPV1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113660932-B | Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240124442-A1 | TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS | AMGEN INC. (US) | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124442-A1 | TRICYCLIC-AMIDO-BICYCLIC PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PDPK1 1066/4885SRD5A1 940/4885TRPV1 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.